# | Title | Journal | Year | Citations |
---|
1 | Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults | Alimentary Pharmacology and Therapeutics | 2011 | 2,569 |
2 | Review article: the role of butyrate on colonic function | Alimentary Pharmacology and Therapeutics | 2008 | 2,048 |
3 | The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress | Alimentary Pharmacology and Therapeutics | 1997 | 1,186 |
4 | Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report | Alimentary Pharmacology and Therapeutics | 2002 | 1,068 |
5 | Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis | Alimentary Pharmacology and Therapeutics | 2009 | 703 |
6 | Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis | Alimentary Pharmacology and Therapeutics | 1997 | 700 |
7 | Review article: gastrointestinal features in COVID‐19 and the possibility of faecal transmission | Alimentary Pharmacology and Therapeutics | 2020 | 679 |
8 | A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis | Alimentary Pharmacology and Therapeutics | 2005 | 676 |
9 | Increasing prevalence of coeliac disease over time | Alimentary Pharmacology and Therapeutics | 2007 | 662 |
10 | The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects | Alimentary Pharmacology and Therapeutics | 2003 | 654 |
11 | Review article: the global emergence ofHelicobacter pyloriantibiotic resistance | Alimentary Pharmacology and Therapeutics | 2016 | 546 |
12 | Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease | Alimentary Pharmacology and Therapeutics | 2006 | 543 |
13 | Review article: prebiotics in the gastrointestinal tract | Alimentary Pharmacology and Therapeutics | 2006 | 536 |
14 | Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging | Alimentary Pharmacology and Therapeutics | 2005 | 522 |
15 | Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease | Alimentary Pharmacology and Therapeutics | 2011 | 513 |
16 | Review article: bifidobacteria as probiotic agents - physiological effects and clinical benefits | Alimentary Pharmacology and Therapeutics | 2005 | 507 |
17 | Development of the GerdQ, a tool for the diagnosis and management of gastro‐oesophageal reflux disease in primary care | Alimentary Pharmacology and Therapeutics | 2009 | 497 |
18 | Systematic review with meta‐analysis: the worldwide prevalence of Helicobacter pylori infection | Alimentary Pharmacology and Therapeutics | 2018 | 497 |
19 | Review article: loss of response to anti-TNF treatments in Crohn’s disease | Alimentary Pharmacology and Therapeutics | 2011 | 495 |
20 | Colorectal cancer prevention in ulcerative colitis: a case-control study | Alimentary Pharmacology and Therapeutics | 2000 | 492 |
21 | Chronic constipation: a survey of the patient perspective | Alimentary Pharmacology and Therapeutics | 2007 | 492 |
22 | Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis | Alimentary Pharmacology and Therapeutics | 1999 | 485 |
23 | Review article: short chain fatty acids in health and disease | Alimentary Pharmacology and Therapeutics | 1998 | 478 |
24 | Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome | Alimentary Pharmacology and Therapeutics | 2009 | 467 |
25 | Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection | Alimentary Pharmacology and Therapeutics | 2015 | 467 |
26 | Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease | Alimentary Pharmacology and Therapeutics | 2003 | 466 |
27 | Systematic review with meta‐analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection | Alimentary Pharmacology and Therapeutics | 2017 | 455 |
28 | Review article: dietary fibre-microbiota interactions | Alimentary Pharmacology and Therapeutics | 2015 | 430 |
29 | Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility | Alimentary Pharmacology and Therapeutics | 2004 | 428 |
30 | Review article: yeast as probiotics –Saccharomyces boulardii | Alimentary Pharmacology and Therapeutics | 2007 | 428 |
31 | Review article: lactose intolerance in clinical practice – myths and realities | Alimentary Pharmacology and Therapeutics | 2008 | 426 |
32 | Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation | Alimentary Pharmacology and Therapeutics | 2001 | 425 |
33 | Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome | Alimentary Pharmacology and Therapeutics | 2018 | 423 |
34 | A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome | Alimentary Pharmacology and Therapeutics | 2003 | 416 |
35 | Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact | Alimentary Pharmacology and Therapeutics | 2005 | 413 |
36 | Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double‐blind placebo‐controlled trial | Alimentary Pharmacology and Therapeutics | 1995 | 413 |
37 | The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review | Alimentary Pharmacology and Therapeutics | 2002 | 403 |
38 | Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis | Alimentary Pharmacology and Therapeutics | 2006 | 403 |
39 | Systematic review: the global incidence and prevalence of peptic ulcer disease | Alimentary Pharmacology and Therapeutics | 2009 | 398 |
40 | Systematic review: impact of constipation on quality of life in adults and children | Alimentary Pharmacology and Therapeutics | 2010 | 392 |
41 | Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients | Alimentary Pharmacology and Therapeutics | 2014 | 389 |
42 | Systematic review and meta‐analysis: the incidence and prognosis of post‐infectious irritable bowel syndrome | Alimentary Pharmacology and Therapeutics | 2007 | 387 |
43 | Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection | Alimentary Pharmacology and Therapeutics | 2011 | 377 |
44 | Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study | Alimentary Pharmacology and Therapeutics | 2001 | 370 |
45 | Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study | Alimentary Pharmacology and Therapeutics | 2006 | 368 |
46 | Review article: the epidemiology and prevention of gastric cancer | Alimentary Pharmacology and Therapeutics | 2014 | 368 |
47 | Natural history and epidemiology ofHelicobacter pyloriinfection | Alimentary Pharmacology and Therapeutics | 2002 | 364 |
48 | Adipokines and cytokines in non‐alcoholic fatty liver disease | Alimentary Pharmacology and Therapeutics | 2008 | 364 |
49 | Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis | Alimentary Pharmacology and Therapeutics | 2014 | 363 |
50 | Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole | Alimentary Pharmacology and Therapeutics | 1999 | 362 |